Compare CHR & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | COYA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 126.6M |
| IPO Year | N/A | 2022 |
| Metric | CHR | COYA |
|---|---|---|
| Price | $1.67 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 58.6K | ★ 156.4K |
| Earning Date | 03-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $0.03 | $3.71 |
| 52 Week High | $2.71 | $7.75 |
| Indicator | CHR | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 47.66 |
| Support Level | $1.43 | $3.83 |
| Resistance Level | $1.85 | $5.16 |
| Average True Range (ATR) | 0.24 | 0.30 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 30.82 | 36.44 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerReal, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.